Latest research on Lucentis

Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline (tetracycline is not detectable in the final product). Ranibizumab is marketed under the name Lucentis®. It is indicated for the treatment of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.

Lucentis indications

Ranibizumab (Lucentis) was determined effective by two pivotal trials: the MARINA (minimally classic/occult trial of the anti-VEGF antibody ranibizumab in the treatment of neovascular AMD) and ANCHOR (anti-VEGF antibody for the treatment of predominantly classic choroidal neovascularisation in AMD) trials. [source, 2015]
In response to this, the CATT (Comparison of AMD Treatments Trials) and IVAN (Lucentis and Avastin effective in treating wet AMD) studies aimed to compare the safety and efficacy of using ranibizumab versus bevacizumab [41, 42]. [source, 2015]
The aim of this study was to evaluate the effects of intravitreal injection of 0.5 mg/0.05 ml ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA), a VEGF inhibitor, on visual acuity and anatomic results in treatment of macular edema due to RVO. [source, 2015]
Humanized anti-VEGF monoclonal antibodies, like bevacizumab (Avastin(r)), which was approved by the FDA in February 2004, or ranibizumab (Lucentis(r)), have proven their effectiveness in some cancers, but still not in osteosarcoma. [source, 2014]
Additionally, most of these patients were converted due to a physician perception that there was a limited degree of effect, or duration of effect, from their previous therapy (Avastin or Lucentis). [source, 2014]
Lucentis, Avastin and Eyelea are equally effective in exudative AMD. [source, 2014]
Among these therapeutic agents, the anti-VEGF antibody drugs, ranibizumab (Lucentis, Genentech, South San Francisco, CA), bevacizumab (Avastin, Genentech), and aflibercept (Eylea, Bayer HealthCare, Berlin, Germany) are most widely used to treat AMD in the clinical setting, and have similar efficacy and side effects [4]–[6]. [source, 2014]
In the current study, we evaluate the visual outcomes, adverse events, and the effect of cataract extraction by phacoemulsification surgery on the progression of neovascular AMD in eyes treated with intravitreal ranibizumab (Lucentis) injections. [source, 2014]
In our study, the intravitreal therapy of PCME has proven to be effective for both, through the use of anti-VEGF Lucentis, and of Dexamethasone (Ozurdex) in order to obtain the reduction of CME and the normalization of the foveal thickness. [source, 2014]
Patients were treated with the commercially available intravitreal injections of ranibizumab 0.5 mg (Lucentis) as per the investigators' judgement and guided by the current EU SmPC in effect during the time of the study, During the study period (September 30, 2008, to November 15, 2011), the SmPC was updated nine times and all SmPC versions before September 2011 had the same retreatment criteria. [source, 2014]